NVIDIA’s $250M, five-year compute donation funds UK agentic AI safety research, with implications for how GMP teams validate and govern autonomous AI.
News|Articles|December 21, 2015
PTSM: Pharmaceutical Technology Sourcing and Management
- PTSM: Pharmaceutical Technology Sourcing and Management-01-06-2016
- Volume 12
- Issue 1
GENEWIZ Acquires Beckman Coulter Gene Services
Author(s)Pharmaceutical Technology Editors
GENEWIZ signs definitive agreement to acquire Beckman Coulter's gene services business.
Advertisement
Genomics service provider, GENEWIZ, has signed a definitive agreement to acquire the genomic services business of Beckman Coulter (GS), according to a Dec. 21, 2015 announcement.
GENEWIZ provides Sanger DNA sequencing, gene synthesis, next generation sequencing, molecular biology bioinformatics, and GLP/GLIA regulatory services. The gene sequencing division of Beckman Coulter provides Sanger and next generation gene sequencing services, with bioinformatics services.
This acquisition will support GENEWIZ’s global expansion strategy by leveraging GS’s 25-plus years of genomics capabilities. It will also aid the company’s international expansion by adding additional locations in the US, UK, China, and Japan.
The agreement was approved by the boards of directors of both companies and closed immediately.
Source:
Articles in this issue
almost 11 years ago
CMO Consolidation Pace May Slow Downalmost 11 years ago
Branded and Generic APIs Look to Strong 2016almost 11 years ago
Sun Pharmaceutical Issued Warning Letter for Microbial Violationsalmost 11 years ago
Collaboration Seeks to Reduce Animal Testingalmost 11 years ago
Recipharm Signs Agreement to Manufacture Liproca Depotalmost 11 years ago
AMRI Acquires Whitehouse Laboratoriesalmost 11 years ago
Quotient Clinical Acquires Co-Formulate Limitedalmost 11 years ago
Capsugel to Acquire Xcelience and Powdersizealmost 11 years ago
FDA Warns of Potential Baclofen API Contaminationalmost 11 years ago
Althea Expands Biological Drug Product Manufacturing OperationsAdvertisement
Related to this article
Richard Jaenisch explains what FDA's real-world use case database means for CMC and quality teams navigating NAMs.
This article examines how modern automation platforms create the digital foundation required for Pharma 4.0 by integrating manufacturing systems, centralized data management, Industrial Internet of Things connectivity, electronic batch production records, and AI-driven analytics.
Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.
Jason Bertola, executive director of Commercial Development for the Advanced Synthesis Platform at Lonza in North America, explains the demand for spray drying and the hurdles involved with scale up, in an interview with PharmTech.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
FDA Rare Disease Framework Puts CMC Review in Scope
2
Clinical Trial Delays: FDA’s Expedited IND Pilot vs China’s 818 Decree
3
PharmTech AI Pulse Check: AI Watermark Vulnerability
4
Using Automation to Enhance Manufacturing: Building the Foundation for Pharma 4.0
5